Effect of Dotinurad on Uric Acid and Hepatorenal Parameters in Steatotic Liver Disease: A Pilot Study in Japanese Patients

<b>Background:</b> Dotinurad (DOT) has demonstrated beneficial metabolic effects in preclinical models as a selective uric acid reabsorption inhibitor. However, its clinical impact on steatotic liver disease (SLD) with hyperuricemia (HU-SLD) remains unclear. <b>Methods:</b> This observational pilot...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Yuma Kamijo, Takanobu Iwadare, Takefumi Kimura, Kaede Fujita, Taiki Okumura, Shun-ichi Wakabayashi, Hiroyuki Kobayashi, Tomoo Yamazaki, Naoki Tanaka, Hideo Kunimoto
Format:	Artigo
Sprog:	Inglês
Udgivet:	MDPI AG 2025-11-01
Serier:	Biomedicines
Fag:	alcohol-related liver disease dotinurad hyperuricemia metabolic dysfunction-associated steatotic liver disease selective urate transporter 1 modulator steatotic liver disease
Online adgang:	https://www.mdpi.com/2227-9059/13/11/2716
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!